SLC5A2 and type 2 diabetes mellitus: Current guidelines [10, 12] recommend combining SGLT2 inhibitors and GLP-1 RAs to further reduce cardiorenal risk in individuals with type 2 diabetes and established CVD or multiple cardiovascular risk factors.